Eastham et al. have recently reported — in the Journal of Clinical Oncology — results from a randomized Phase III trial of the surgical treatment of men with high-risk forms of localized prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: "high risk", ADT, androgen, chemohormonal, chemotherapy, CHT, deprivation, localized, neoadjuvant, prostatectomy, radical, trial | 1 Comment »
It remains unclear at this time whether the early use of chemotherapy in carefully selected men with intermediate- and high-risk forms of prostate cancer (while the cancer is still believed to be limited in its spread) is associated with superior clinical outcomes compared to other forms of therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: chemohormonal, chemotherapy, early, therapy | 3 Comments »
Several years ago, Bolla et al. planned and carried out the major European trial showing that external beam radiation therapy with 3 years of androgen deprivation therapy (ADT, using goserelin acetate) extended the prostate cancer-specific and the overall survival of patients with high-risk localized prostate cancer as compared to radiation alone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 3D-CRT, ADT, androgen deprivation therapy, chemohormonal, docetaxel, radiation | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 